Tuesday, 12 Nov 2019

RA/Inflammatory arthritis

Datesort ascending Type Title Save
11 Jul 2019 Social Study of 182 hospitalized adult-onset Still's disease patients shows predictive factors for developing macrophage activation syndrome to include: 1. Splenomegaly (OR 5.745), 2. pericarditis (OR 6.5), and 3. ferritin >2000 (OR 4.7). https://t.co/oNsaCL6O92
11 Jul 2019 News CRP Utility in COPD Exacerbations
08 Jul 2019 Slide of the day RA and Comorbidities
05 Jul 2019 Social RT @RheumNow: Dr. Kevin Winthrop at #EULAR2019 during his infection lecture delivers the Pearl that Tofacitinib pts found to have Latent TB…
05 Jul 2019 Social RT @RheumNow: Dr. Gerd Burmester reviews the SEMIRA study that examines whether or not you should wean that 5mg Prednisone in your RA patie…
04 Jul 2019 Social RT @RheumNow: Shingrix can be give to inflammatory arthritis pts? Collective report from the Brigham & Women’s Hospital looked at the safet…
03 Jul 2019 Social RT @drdavidliew: Good lessons from 22,607 RA patients from the UK CPRD: cataracts and glaucoma from pred are dose dependent, and even 1000m…
01 Jul 2019 Social #EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA (Stills) patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/9mtxPkHZr3
01 Jul 2019 Social RT @drdavidliew: We need to talk about repeated ANAs - good lessons from the plenary hall today about 7875 repeated ANA tests from a single…
01 Jul 2019 News EULAR 2019 - Day 1 Report
01 Jul 2019 Social 795 RA patients from the GIRRCS cohort 3 yr study found that maintaining remission reduced the incidence of subclinical atherosclerosis by three-quarters (OR = 0.25; P = .001). (87% were on MTX; 60% on biologics) #EULAR2019 ABST# OP0090 https://t.co/RvRcXsDnKs
27 Jun 2019 Social A Western Norway study of GCA (1972–2012) compared 792 GCA (528 Bx-verified) to 2577 matched controls. There were no differences in overall survival (p=0.41). GCA had higher risk of CV death (HR 1.31) but lower risk of cancer deaths (HR 0.56). https://t.co/oBx2kBTyrZ
26 Jun 2019 Social 795 RA patients from the GIRRCS cohort 3 year study found that maintaining remission reduced the incidence of subclinical atherosclerosis by three-quarters (OR = 0.25; P = .001). (87% were on MTX; 60% on biologics) #EULAR2019 ABST# OP0090 https://t.co/RvRcXsDnKs
25 Jun 2019 Social 137 consecutive RA pts were evaluated by electronic stethoscopy of 4 lung fields to identify "VELCRO" lung sounds as an indicator of early ILD by HRCT. Sensitivity =93.2% and specificity=76.9%, Dx accuracy =83.9%. correctly classified 115/137 pts. https://t.co/0HWYLvgmTL
21 Jun 2019 Social "Clinicians should assess test results based on the person's likelihood of infection and risk for progression to TB disease, if infected," according to the CDC. MMWR. 2019;68:552-553. https://t.co/eJGOHVCbkO
21 Jun 2019 ACR Video Dr. Gerd Burmester reviews the SEMIRA study from EULAR 2019
21 Jun 2019 ACR Video Riociquat in Scleroderma ILD
20 Jun 2019 Social FORWARD, a National Databank study, looked at malignancies & infections in RA pts starting abatacept, other biologicsor DMARDs. No difference in cancer risks, but ABA had lower risk hospitalized infx (HR 0.37) & lower infusion/injx rxn than other biologics https://t.co/9GonhVTK3Z
19 Jun 2019 Slide of the day AOSD Diagnostic Criteria
19 Jun 2019 Social #EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/5K58IUNdCV